Oppenheimer & Co. Inc. Purchases 4,811 Shares of Biogen Inc. $BIIB

Oppenheimer & Co. Inc. lifted its position in Biogen Inc. (NASDAQ:BIIB) by 180.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,477 shares of the biotechnology company’s stock after purchasing an additional 4,811 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Biogen were worth $1,689,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in Biogen in the 2nd quarter worth about $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen during the 2nd quarter worth $3,274,304,000. Wellington Management Group LLP lifted its holdings in shares of Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after acquiring an additional 155,828 shares during the last quarter. Amundi grew its position in Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after acquiring an additional 726,004 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Biogen in the second quarter worth $322,640,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Analyst Ratings Changes

Several equities research analysts have issued reports on BIIB shares. HSBC lifted their price target on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Morgan Stanley increased their price objective on Biogen from $231.00 to $238.00 and gave the company an “equal weight” rating in a research report on Thursday. Truist Financial reissued a “buy” rating and set a $260.00 price objective (up from $235.00) on shares of Biogen in a report on Thursday. Wells Fargo & Company boosted their target price on Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 20th. Finally, Royal Bank Of Canada upped their target price on Biogen from $256.00 to $272.00 and gave the stock an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and an average price target of $251.00.

Biogen Price Performance

Shares of Biogen stock opened at $253.62 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. Biogen Inc. has a 52-week low of $146.52 and a 52-week high of $258.78. The company’s 50 day moving average price is $227.08 and its 200-day moving average price is $201.04. The stock has a market capitalization of $37.49 billion, a price-to-earnings ratio of 108.38, a P/E/G ratio of 2.88 and a beta of 0.10.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. During the same period last year, the company earned $4.81 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. Equities research analysts forecast that Biogen Inc. will post 12.44 EPS for the current year.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.